Enbrel, a recombinant fusion protein that blocks tumor necrosis factor, is used to treat rheumatoid arthritis and psoriasis, and generated $1.69 billion in US sales for Amgen in the first half of ...

Etanercept (Enbrel ®) is an injectable fusion protein that competitively inhibits the pro-inflammatory cytokine TNF-α. It is approved for use in rheumatoid arthritis, juvenile rheumatoid ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...

In addition, the class of fusion-protein inhibitors (led by Enbrel) will see its sales almost tripled from $2,299m in 2004 to $6,366m in 2010, while its market shares will grow from 7% to 12%.

Amgen’s venerable TNF inhibitor Enbrel (etanercept) for arthritis and other inflammatory conditions topped the list of offenders in terms of the added cost to the healthcare system, which ICER ...